Bluebird Bio reported $158.86M in Equity Capital and Reserves for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Agios Pharmaceuticals AGIO:US USD 1.1B 50.64M
Alnylam Pharmaceuticals ALNY:US USD -158223000 90.58M
Amgen AMGN:US USD 3.66B 8M
Arrowhead Research ARWR:US USD 377.04M 21.48M
Avrobio Inc AVRO:US USD 75.37M 22.72M
Biogen BIIB:US USD 13.4B 622.4M
Biomarin Pharmaceutical BMRN:US USD 4.6B 34.64M
Bluebird Bio BLUE:US USD 158.86M 21.26M
Gilead Sciences GILD:US USD 21.21B 128M
Immunogen IMGN:US USD 155.83M 22.18M
Intercept Pharmaceuticals ICPT:US USD 93.08M 14.6M
Mirati Therapeutics MRTX:US USD 996.52M 132.54M
Moderna Inc MRNA:US USD 19.12B 1.13B
Nektar Therapeutics NKTR:US USD 366.64M 45.58M
Novartis NOVN:VX USD 59.34B 1.48B
Ptc Therapeutics PTCT:US USD -347086000 120.18M
Regeneron Pharmaceuticals REGN:US USD 22.66B 1.23B
Sangamo Biosciences SGMO:US USD 294.96M 14.2M
Sarepta Therapeutics SRPT:US USD 384.95M 45.89M
Seattle Genetics SGEN:US USD 2.8B 17.99M
Ultragenyx Pharmaceutical RARE:US USD 352.49M 116.34M
Vertex Pharmaceuticals VRTX:US USD 13.91B 883.1M
YTE INCY:US USD 4.37B 143.47M